Profil
Ed Gemo ist Chief Information Officer & Senior Vice President von Turning Point Therapeutics, Inc. In der Vergangenheit hatte Ed Gemo die Position des Chief Information & Security Officer, VP bei Halozyme Therapeutics, Inc. inne, Chief Information Officer & Vice President bei Onyx Pharmaceuticals, Inc. und Chief Information Officer & Senior Vice President bei InterMune, Inc. Er erhielt einen Undergraduate-Abschluss vom Brooklyn College und einen MBA von der Pace University.
Aktive Positionen von Ed Gemo
| Unternehmen | Position | Beginn |
|---|---|---|
| TURG POIN | Chief Tech/Sci/R&D Officer | - |
Ehemalige bekannte Positionen von Ed Gemo
| Unternehmen | Position | Ende |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | - |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Ed Gemo
| Brooklyn College | Undergraduate Degree |
| Pace University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
